With 2.54 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.2 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $2.0 whereas the lowest price it dropped to was $1.35. The 52-week range on CHEK shows that it touched its highest point at $3.45 and its lowest point at $0.56 during that stretch. It currently has a 1-year price target of $7.00. Beta for the stock currently stands at 0.06.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CHEK was up-trending over the past week, with a rise of 42.61%, but this was up by 102.47% over a month. Three-month performance surged to 10.07% while six-month performance fell -16.33%. The stock lost -20.00% in the past year, while it has gained 65.67% so far this year.
Float and Shares Shorts:
At present, 5.85 million CHEK shares are outstanding with a float of 4.38 million shares on hand for trading. On 2024-12-13, short shares totaled 9845.0, which was 17.0 higher than short shares on 1731628800. In addition to Dr. Yoav Kimchy Ph.D. as the firm’s Founder, Head of R&D and Member of Scientific Advisory Board, David Benaim serves as its Interim Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.0023100001 of CHEK’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2023-12-31, CHEK reported revenue of $0.0 and operating income of -$3991000.0. The EBITDA in the recently reported quarter was -$3625000.0 and diluted EPS was $nan.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
Analysts have provided yearly estimates in a range of -$2.51 being high and -$2.51 being low. For CHEK, this leads to a yearly average estimate of -$2.51.
